Organoid technology and applications in cancer immunotherapy and precision medicine.

Details

Serval ID
serval:BIB_BB24203665BA
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Organoid technology and applications in cancer immunotherapy and precision medicine.
Journal
Current opinion in biotechnology
Author(s)
Homicsko K.
ISSN
1879-0429 (Electronic)
ISSN-L
0958-1669
Publication state
Published
Issued date
27/06/2020
Peer-reviewed
Oui
Volume
65
Pages
242-247
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: aheadofprint
Abstract
Tumors are complex ecosystems of multiple cell types in addition to cancer cells. The response to therapies can be shaped by not only cancer cell vulnerabilities but also by the cells of the tumor microenvironment (TME). For cellular immune therapies, cancer cells are the direct target, but for most of the immune checkpoint blockades (ICB), the direct therapeutic targets are the immune cells. Current immune therapy approaches, especially immune checkpoint blockades, only work for select patient populations. A pre-treatment, ex vivo assay could help in selecting between immune therapy options. However, for immune therapy applications, ex vivo assays would require the co-culturing of both cancer cells and cells of the TME. New results show that it is now feasible to co-culture both cell types with organoid technologies. However, many challenges remain to both optimize organoid cultures as well as to validate ex vivo assays as predictors of therapeutic benefits from immune therapies.
Pubmed
Create date
03/07/2020 16:00
Last modification date
29/10/2020 6:26
Usage data